Luminex Corporation (LMNX)

NASDAQ
36.99
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    36.98 - 37.00

LMNX Overview

Prev. Close
36.99
Day's Range
36.98-37
Revenue
528.08M
Open
37
52 wk Range
20.61-41.25
EPS
0.5
Volume
0
Market Cap
1.75B
Dividend (Yield)
0.40
(1.08%)
Average Volume (3m)
582,991
P/E Ratio
74.08
Beta
0.57
1-Year Change
0.74%
Shares Outstanding
47,311,982
Next Earnings Date
08 Aug 2021
What is your sentiment on Luminex Corporation?
or
Market is currently closed. Voting is open during market hours.

Luminex Corporation News

  • Luminex declares $0.10 dividend
    • BySeeking Alpha-

    Luminex (NASDAQ:LMNX) declares $0.10/share quarterly dividend, in line with previous.Forward yield 1.09%Payable July 8; for shareholders of record June 17; ex-div June 16.See LMNX...

  • Tesla, Alibaba and Uber Rise Premarket
    • ByInvesting.com-

    By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, April 12th. Please refresh for updates. Nuance Communications (NASDAQ:NUAN) stock soared 22%...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsSellSellBuyStrong BuyStrong Buy
SummaryNeutralNeutralStrong BuyStrong BuyStrong Buy

Luminex Corporation Company Profile

Luminex Corporation Company Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. The company was founded in 1995 and is based in Austin, Texas. It has additional offices in Northbrook, Illinois; Madison, Wisconsin; Seattle, Washington; ‘s-Hertogenbosch, the Netherlands; Shanghai, China; Kowloon, Hong Kong; Tokyo, Japan; and Toronto, Canada. As of July 14, 2021, Luminex Corporation operates as a subsidiary of DiaSorin S.p.A.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.